MYOV News and Press, Myovant Sciences Ltd. From 10/31/19

Sumitomo Dainippon Pharma to provide Myovant Sciences with a $350 million, low-interest, five-year term loan facility, with no repayments due until the end of the term Opportunity to access Sumitomo Dainippon Pharma’s commercial infrastructure and operational support for planned re...

Top-line results for SPIRIT 2 and SPIRIT 1 expected in the first and second quarters of 2020, respectively Studies support potential regulatory submission for a single tablet, once-daily treatment of moderate-to-severe endometriosis-associated pain BRISBANE, Calif. and BASEL, Switzerla...

BASEL, Switzerland and SAN MATEO, Calif., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Pervasive stigma and prevalent symptoms related to menstruation are among the key takeaways from a new survey conducted by Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative tr...

BRISBANE, Calif., and BASEL, Switzerland, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, announced today the formation of Female Forward Together, a cross-sector...

Biotech is in the doldrums. The SPDR S&P Biotech ETF  declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...

BRISBANE, Calif., and BASEL, Switzerland, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Myovant   Sciences (NYSE:  MYOV ), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that results from its Phase 3 LIBERTY 1 & 2 s...

Myovant Sciences' (NYSE: MYOV ) founding shareholder, Roivant Sciences, and Sumitomo Dainippon Pharma ( OTC:SMDPY ) have announced their entry into a non-binding memorandum of understanding (MOU) for the creation of a broad strategic alliance. More news on: Myovant Sc...

Roivant’s ownership interest in Myovant Sciences (approximately 46% of shares issued and outstanding) to be fully assumed by a new entity, Sumitomo Dainippon-Roivant Alliance, which will be wholly owned by Sumitomo Dainippon Pharma   Sumitomo Dainippon-Roivant Alliance to prov...

Thinly traded Myovant Sciences ( MYOV +0.1% ) has rallied  ~25%  since August 6 when in reported fiscal Q1 results (calendar Q2) that included a pipeline update. More news on: Myovant Sciences Ltd., AbbVie Inc., Healthcare stocks news, Read more ...

BRISBANE, Calif. and BASEL, Switzerland, Aug. 27, 2019 (GLOBE NEWSWIRE) -- A correction has been issued for the release disseminated today at 8:30 AM ET. The date for Lynn Seely's presentation was incorrectly listed. The complete and corrected release follows: Myovant Sciences (NYSE: ...